These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Cellular heterogeneity of CFTR expression and function in the lung: implications for gene therapy of cystic fibrosis. Jiang Q; Engelhardt JF Eur J Hum Genet; 1998 Jan; 6(1):12-31. PubMed ID: 9781011 [TBL] [Abstract][Full Text] [Related]
8. Modulation of Ion Transport to Restore Airway Hydration in Cystic Fibrosis. Reihill JA; Douglas LEJ; Martin SL Genes (Basel); 2021 Mar; 12(3):. PubMed ID: 33810137 [TBL] [Abstract][Full Text] [Related]
9. Pharmacotherapy of the ion transport defect in cystic fibrosis: role of purinergic receptor agonists and other potential therapeutics. Kunzelmann K; Mall M Am J Respir Med; 2003; 2(4):299-309. PubMed ID: 14719996 [TBL] [Abstract][Full Text] [Related]
10. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects. Kuk K; Taylor-Cousar JL Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827 [TBL] [Abstract][Full Text] [Related]
11. Unified Airway-Cystic Fibrosis. Cho DY; Grayson JW; Woodworth BA Otolaryngol Clin North Am; 2023 Feb; 56(1):125-136. PubMed ID: 36266104 [TBL] [Abstract][Full Text] [Related]
12. Progress in understanding mucus abnormalities in cystic fibrosis airways. Wine JJ; Hansson GC; König P; Joo NS; Ermund A; Pieper M J Cyst Fibros; 2018 Mar; 17(2S):S35-S39. PubMed ID: 28951068 [TBL] [Abstract][Full Text] [Related]
14. What's new in cystic fibrosis? From treating symptoms to correction of the basic defect. Proesmans M; Vermeulen F; De Boeck K Eur J Pediatr; 2008 Aug; 167(8):839-49. PubMed ID: 18389279 [TBL] [Abstract][Full Text] [Related]
15. The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis. Shei RJ; Peabody JE; Kaza N; Rowe SM Curr Opin Pharmacol; 2018 Dec; 43():152-165. PubMed ID: 30340955 [TBL] [Abstract][Full Text] [Related]
16. The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis lung disease. Moore PJ; Tarran R Expert Opin Ther Targets; 2018 Aug; 22(8):687-701. PubMed ID: 30028216 [TBL] [Abstract][Full Text] [Related]
17. Role of airway surface liquid and submucosal glands in cystic fibrosis lung disease. Verkman AS; Song Y; Thiagarajah JR Am J Physiol Cell Physiol; 2003 Jan; 284(1):C2-15. PubMed ID: 12475759 [TBL] [Abstract][Full Text] [Related]
18. Hyperacidification in cystic fibrosis: links with lung disease and new prospects for treatment. Poschet J; Perkett E; Deretic V Trends Mol Med; 2002 Nov; 8(11):512-9. PubMed ID: 12421684 [TBL] [Abstract][Full Text] [Related]
19. Immunopathology of Airway Surface Liquid Dehydration Disease. Lewis BW; Patial S; Saini Y J Immunol Res; 2019; 2019():2180409. PubMed ID: 31396541 [TBL] [Abstract][Full Text] [Related]
20. [Physiopathology of cystic fibrosis lung disease]. Chinet T Rev Mal Respir; 1999 Jun; 16(3):339-45. PubMed ID: 10472642 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]